SouthState Corp’s Y-mAbs Therapeutics YMAB Stock Holding History

SouthState Corp’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-68	Closed	-$302	–	1836
2025 Q1	$302	Buy	+68	New	+$395	﹤0.01%	1614

Other funds holding YMAB

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

SouthState Corp's YMAB Position: Q2 2025 in Review

SouthState Corp sold out of Y-mAbs Therapeutics (YMAB) in Q2 2025, closing a stake of 68 shares — an estimated $302 sold.

SouthState Corp first reported a position in YMAB in Q1 2025 and held it in 1 quarter. The position peaked at $302 in Q1 2025. 97 funds tracked by Wall St. Rank hold YMAB as of Q2 2025.

SouthState Corp reported no remaining Y-mAbs Therapeutics position as of Q2 2025 after selling out during the quarter.
SouthState Corp sold 68 Y-mAbs Therapeutics shares in Q2 2025, an estimated $302.
SouthState Corp first reported a position in Y-mAbs Therapeutics in Q1 2025 and held it in 1 quarter.
SouthState Corp's Y-mAbs Therapeutics position peaked at $302 in Q1 2025.
97 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2025.

Based on SouthState Corp's 13F filing for Q2 2025, filed 6 Aug 2025.